May 2026 · Monthly report test
Monthly Cognitive Neurology Update
Clinically focused evidence on the diagnosis, prevention, and treatment of cognitive disorders.
At a glance
View methodologyExecutive summary
14 fully assessed articles: 9 Diagnosis·0 Treatment·3 Reviews·2 Others·6 Priority
Six priority findings were selected for rapid review. This month’s strongest clinical signals concern multimodal biomarker diagnosis of degenerative parkinsonism, risk stratification with plasma p-tau217, emerging blood markers for cerebral amyloid angiopathy, and early recognition of treatable autoimmune rapidly progressive dementia.
Selected by clinical relevance
6 priority findings
Evidence library
14 of 14 resultsFully assessed articles
All included records have undergone publication-type verification, DOI/PMID deduplication, and clinical-relevance assessment.
19 May 2026
A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism
Martinez-Valbuena I, et al. · Nature Medicine
Dermal α-synuclein and 4-repeat tau seed amplification assays, combined with serum neurofilament light, improved discrimination among Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy.
Publication type
Original research
Study typeProspective diagnostic cohort with external validation
Clinical relevance
This is directly relevant to patients whose parkinsonian syndrome remains uncertain after clinical assessment, particularly when overlapping features or suspected co-pathology complicate diagnosis.
Current implication: The combined panel is not yet a routine diagnostic standard, but it provides a credible pathway toward biologically informed differential diagnosis across PD, MSA, and PSP.
Key limitation
Specialist cohorts were relatively small, and broader real-world validation, assay standardization, and accessibility studies are still required.
14 May 2026
The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline
Rivera Sánchez M, et al. · Neurology
In 469 people with subjective cognitive decline, a model combining cognition, plasma p-tau217, and APOE ε4 predicted progression to Alzheimer dementia with a C-index of 0.91; MRI added little for Alzheimer-specific prediction.
Publication type
Original research
Study typeLongitudinal observational cohort study
Clinical relevance
The study addresses a common memory-clinic problem: identifying which patients with subjective decline are at meaningful risk of progression while avoiding unnecessary escalation in low-risk patients.
Current implication: A clinically feasible combination of cognitive testing and plasma p-tau217 could support risk stratification, but it should complement—not replace—clinical assessment and appropriate confirmatory pathways.
Key limitation
The cohorts came from a specialized research setting, and calibration across more diverse memory-clinic populations is needed.
May 2026
Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer’s disease (HEAD)
Povala G, et al.; HEAD Study · The Lancet
Among 682 participants completing both scans, [18F]MK6240 detected more medial temporal and neocortical tau pathology and discriminated Alzheimer-related cognitive impairment more accurately than [18F]flortaucipir.
Publication type
Original research
Study typeProspective multicentre within-participant diagnostic comparison
Clinical relevance
Tracer choice can materially change tau-positive classification and therefore influence trial selection, staging, and potentially therapeutic decision-making.
Current implication: Results should not be transferred directly between tau tracers. Local interpretation thresholds and the tracer used must be considered when applying tau PET clinically.
Key limitation
[18F]MK6240 remains investigational, the comparison was non-randomized, and the cohort had limited ethnoracial diversity.
20 May 2026
A plasma protein signature for cerebral amyloid angiopathy
Singh A, et al. · Acta Neuropathologica
A five-protein plasma panel combined with demographics identified neuropathologically confirmed cerebral amyloid angiopathy with an AUC of 0.90 in the discovery cohort and showed added value in an independent cohort.
Publication type
Original research
Study typeNeuropathology-anchored biomarker discovery and external validation study
Clinical relevance
A reliable blood-based CAA signal could improve diagnostic assessment and anti-amyloid treatment risk stratification, particularly for amyloid-related imaging abnormalities.
Current implication: The panel is promising but exploratory; it should not yet determine anti-amyloid eligibility or monitoring without prospective clinical validation.
Key limitation
Plasma was compared with later neuropathology, and the independent validation did not establish a ready-to-use clinical threshold.
15 May 2026
Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study
van Steenhoven RW, et al. · Neurology
Autoimmune encephalitis accounted for 39% of 147 rapidly progressive dementia presentations and was the most frequent treatment-responsive cause; early seizures and specific accompanying syndromes helped identify cases.
Publication type
Original research
Study typeProspective multicentre diagnostic cohort study
Clinical relevance
The findings reinforce systematic consideration of autoimmune encephalitis before labeling rapidly progressive cognitive decline as prion or another untreatable neurodegenerative disease.
Current implication: Rapidly progressive dementia pathways should prioritize early clinical pattern recognition and timely serum and CSF autoimmune testing when compatible features are present.
Key limitation
Referral patterns in expert centres may inflate autoimmune encephalitis prevalence relative to general neurology practice.
20 May 2026
Smoking Cessation, Weight Change, and Risk of Dementia: A Prospective Cohort Study
Chen H, et al. · Neurology
Smoking cessation was associated with lower dementia risk and slower cognitive decline over long-term follow-up; substantial post-cessation weight gain appeared to attenuate the association.
Publication type
Primary prevention cohort study
Study typeProspective population-based cohort study
Clinical relevance
This provides an actionable prevention message for cognitive clinics and highlights weight management as part of smoking-cessation counselling.
Current implication: Clinicians can reinforce smoking cessation as part of dementia-risk reduction while proactively supporting healthy weight after quitting.
Key limitation
The observational design remains vulnerable to residual confounding, self-report error, and reverse causation.
14 May 2026
Diagnostic, Prognostic Value, and Pathological Associations of Levodopa Responsiveness in Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
Arca VM, et al. · Annals of Neurology
A sustained long-duration levodopa response distinguished Parkinson’s disease from MSA and PSP with 86.4% sensitivity and 95.8% specificity and was associated with lower dementia risk and better survival in PD.
4 May 2026
Cerebral Amyloid Angiopathy and Risk of Dementia in Patients With Cognitive Complaint
Raposo N, et al.; MEMENTO Study Group · Neurology
Probable CAA was common among nondemented memory-clinic patients and was associated with greater dementia risk, although results differed between Boston criteria versions and attenuated after additional adjustment.
7 May 2026
Predictive value of cerebrospinal fluid Alzheimer’s disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson’s disease
Scalese A, et al. · Brain Communications
In 78 patients with Parkinson’s disease, CSF amyloid and tau measures showed domain-specific cognitive associations and predicted aspects of cognitive and motor progression over 18–24 months.
27 May 2026
Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing
Khorsand B, et al. · Alzheimer’s & Dementia
Plasma p-tau217, subjective cognitive concerns, and computerized cognitive performance independently predicted conversion from normal cognition to measurable impairment over 240 weeks.
4 May 2026
What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?
Hazan J, et al. · Neurology
The article examines uncertainty around testing, counselling, prognosis, and management after a positive Alzheimer blood biomarker result in a person with mild cognitive impairment.
15 May 2026
Molecular signatures and biomarker development for limbic-predominant age-related TDP-43 encephalopathy (LATE)
Wu L, et al. · Acta Neuropathologica
The review synthesizes current molecular, imaging, blood, and CSF biomarker work for LATE and discusses recent consensus approaches to predicting LATE neuropathologic change during life.
8 May 2026
Advanced diffusion MRI tract signatures in Alzheimer’s disease, dementia with Lewy bodies, and the FTD/PPA spectrum
Tian Y, Whitwell JL. · NeuroImage
The review describes shared and disease-specific tract signatures across Alzheimer’s disease, DLB, FTD, and PPA and finds that advanced diffusion models often outperform conventional diffusion tensor imaging.
18 May 2026
Changes in arterial stiffness under blood pressure control are independently associated with cognitive impairment: The SPRINT trial
Hughes TM, et al. · Alzheimer’s & Dementia
In the SPRINT pulse-wave-velocity substudy, reductions in load-dependent arterial stiffness during intensive blood-pressure control were associated with lower long-term risk of cognitive impairment.
Quality control
Search methodology
Journal and first-publication-date searches were run in Europe PMC/PubMed metadata and checked against publisher records. Screening was restricted to human studies with direct relevance to cognition, diagnosis, prevention, treatment, or clinically important differential diagnosis.
Date range1–31 May 2026
Candidate records1127
Eligible articles14
Included populationHuman studies only
Detailed search methodology
Search terms
Condition concepts were combined with the following topic concepts and adapted to the syntax of each source:
Diagnosis: diagnos* OR biomarker* OR neuroimaging OR PET OR MRI OR CSF OR plasma OR genetic* OR criteria OR "differential diagnosis" OR screening
Treatment and prevention: treat* OR therap* OR intervention* OR "clinical trial" OR random* OR pharmacolog* OR non-pharmacolog* OR prevention OR safety OR efficacy
- Alzheimer’s disease
"Alzheimer disease" OR Alzheimer*- Cerebral Amyloid Angiopathy
"cerebral amyloid angiopathy" OR CAA- Parkinson’s disease
Parkinson* AND (cognit* OR dementia OR "differential diagnosis")- Dementia with Lewy bodies
"dementia with Lewy bodies" OR DLB OR "Lewy body dementia"- Multiple system atrophy
"multiple system atrophy" OR MSA- Progressive supranuclear palsy
"progressive supranuclear palsy" OR PSP- Corticobasal degeneration
"corticobasal degeneration" OR CBD- Corticobasal syndrome
"corticobasal syndrome" OR CBS- Primary progressive aphasias
"primary progressive aphasia" OR "primary progressive aphasias" OR PPA- Vascular cognitive impairment
"vascular cognitive impairment" OR "vascular cognitive decline" OR "vascular dementia"- Creutzfeldt–Jakob disease (CJD)
"Creutzfeldt-Jakob disease" OR CJD OR "prion disease"- Normal pressure hydrocephalus
"normal pressure hydrocephalus" OR NPH- Limbic-predominant age-related TDP-43 encephalopathy (LATE)
"limbic-predominant age-related TDP-43 encephalopathy" OR "LATE-NC"- Primary age-related tauopathy (PART)
"primary age-related tauopathy" OR PART- Argyrophilic grain disease
"argyrophilic grain disease" OR "argyrophilic grains"- Functional cognitive decline
"functional cognitive decline" OR "functional cognitive disorder" OR FCD
Journals reviewed
Primary journals
- Brain
- JAMA Neurology
- The Lancet Neurology
- The New England Journal of Medicine
- The Lancet
- Annals of Neurology
- Alzheimer’s & Dementia
- Neurology
- Journal of Neurology, Neurosurgery & Psychiatry
- Acta Neuropathologica
- Brain Communications
- Neurobiology of Aging
- Translational Neurodegeneration
- Cortex
- Neuropsychologia
- Neuropsychology
- Journal of Cognitive Neuroscience
- Brain and Cognition
- NeuroImage
- Human Brain Mapping
- Cerebral Cortex
- Cognitive, Affective, & Behavioral Neuroscience
- Molecular Psychiatry
- Biological Psychiatry
- Movement Disorders
- Nature Medicine
- Nature Aging
- Neuron
Review-focused journals
Official journal pages were cross-checked against PubMed, Crossref, and other reliable bibliographic records.
Journal exclusion: Journal of Alzheimer’s Disease is not included in routine surveillance because its very high monthly publication volume would disproportionately increase screening workload and reduce the clinical practicality of the report.
Article selection criteria
Included- New publications within the surveillance period addressing diagnosis, differential diagnosis, primary or secondary prevention, or treatment of an eligible condition.
- Biomarkers, neuroimaging, diagnostic genetics, clinical criteria, pharmacological and non-pharmacological interventions, clinical trials, and treatment safety or efficacy.
- Parkinson’s disease research only when cognition, cognitive impairment, dementia, or a relevant differential diagnosis is a substantial focus.
- Review articles from the designated review-focused journals.
- Clinically substantive letters, editorials, comments, or correspondence may be retained, but must be explicitly labelled by publication type and classified under Others; they are not treated as original research.
- Publications without a substantial connection to cognition, diagnosis, prevention, or treatment.
- Letters, editorials, comments, or correspondence without a substantive clinical contribution.
- Duplicate records identified using DOI, PMID, and normalized title.
- Animal and cellular studies. This version of the report is restricted to human research.
Saved reports
Report archive
Select a published month to reopen its saved report. Opening an archived report never reruns the literature search.